Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Evaxion A/S changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 8 | 10 | +2 |
| Shares | 548.5K | 806.8K | +258.3K (+47.1%) |
| Value | $1.71M | $681.8K | −$1.02M (−60.0%) |
New holders (4)
Institutions that held Evaxion A/S at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Merck & Co., Inc. | 542,279 | $458.4K | 0.18% |
| Catalina Capital Group, LLC | 34,864 | $29.5K | 0.01% |
| Millennium Management LLC | 22,541 | $18.8K | 0.00% |
| SBI Securities Co., Ltd. | 323 | $273 | 0.00% |
Sold out (2)
Institutions that held Evaxion A/S at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Citadel Advisors LLC | 14,825 | $46.1K |
| BlackRock, Inc. | 1,512 | $4.70K |